EDSA vs. CVM, ELYM, OSTX, ALGS, PRLD, LIMN, JMAC, APLT, INKT, and VNRX
Should you be buying Edesa Biotech stock or one of its competitors? The main competitors of Edesa Biotech include CEL-SCI (CVM), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Aligos Therapeutics (ALGS), Prelude Therapeutics (PRLD), Liminatus Pharma (LIMN), Maxpro Capital Acquisition (JMAC), Applied Therapeutics (APLT), MiNK Therapeutics (INKT), and VolitionRx (VNRX). These companies are all part of the "pharmaceutical products" industry.
Edesa Biotech vs. Its Competitors
CEL-SCI (NYSE:CVM) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.
In the previous week, Edesa Biotech had 1 more articles in the media than CEL-SCI. MarketBeat recorded 2 mentions for Edesa Biotech and 1 mentions for CEL-SCI. CEL-SCI's average media sentiment score of 1.81 beat Edesa Biotech's score of 0.00 indicating that CEL-SCI is being referred to more favorably in the media.
Edesa Biotech is trading at a lower price-to-earnings ratio than CEL-SCI, indicating that it is currently the more affordable of the two stocks.
Edesa Biotech has a consensus target price of $5.00, suggesting a potential upside of 104.00%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than CEL-SCI.
CEL-SCI has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.1, indicating that its stock price is 90% less volatile than the S&P 500.
Edesa Biotech's return on equity of -162.95% beat CEL-SCI's return on equity.
12.1% of CEL-SCI shares are held by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are held by institutional investors. 14.1% of CEL-SCI shares are held by insiders. Comparatively, 22.6% of Edesa Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Summary
Edesa Biotech beats CEL-SCI on 10 of the 13 factors compared between the two stocks.
Get Edesa Biotech News Delivered to You Automatically
Sign up to receive the latest news and ratings for EDSA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding EDSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Edesa Biotech Competitors List
Related Companies and Tools
This page (NASDAQ:EDSA) was last updated on 9/10/2025 by MarketBeat.com Staff
Free EDSA Stock Alerts